Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Hematologic Malignancies
Filter by Topic
Leukemia
Elotuzumab-Based Triplet Regimen Stops Progression of High-Risk Smoldering Multiple Myeloma
By
Wayne Kuznar
Hematologic Malignancies
,
Multiple Myeloma
February 2017, Vol 8, No 1
Read Article
American Society of Hematology 2016: Leukemia Highlights
Hematologic Malignancies
,
Leukemia
February 2017, Vol 8, No 1
Read Article
American Society of Hematology 2016: Multiple Myeloma Highlights
Hematologic Malignancies
,
Multiple Myeloma
February 2017, Vol 8, No 1
Read Article
Venetoclax plus Bortezomib and Dexamethasone Produces High Responses in Patients with Relapsed or Refractory Multiple Myeloma
By
Wayne Kuznar
Hematologic Malignancies
,
Multiple Myeloma
February 2017, Vol 8, No 1
San Diego, CA—The addition of venetoclax (Venclexta) to bortezomib (Velcade) and dexamethasone yields high response rates in patients with relapsed or refractory multiple myeloma, especially in patients with disease that is not refractory to bortezomib and who received 1 to 3 previous lines of therapy, according to findings presented by Philippe Moreau, MD, Department of Hematology, Nantes University Hospital, France, at the 2016 American Society of Hematology meeting.
Read Article
Older Drugs in “New Clothes” Achieve Superior Outcomes
By
Phoebe Starr
Hematologic Malignancies
,
Leukemia
,
Personalized Medicine
October 2016, Vol 7, No 9
Read Article
Targeting CD38, Isatuximab Produces Impressive Responses in Relapsed or Refractory Multiple Myeloma
By
Wayne Kuznar
Hematologic Malignancies
,
Multiple Myeloma
,
Personalized Medicine
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Interim results from a phase 1b study indicate that the investigational monoclonal antibody isatuximab, in combination with lenalidomide and dexamethasone, achieves responses in >50% of patients with relapsed or refractory multiple myeloma, including those with disease refractory to immunomodulatory drugs (IMiDs).
Read Article
Three-Drug Regimen with Daratumumab a New Standard of Care for Relapsed or Refractory Multiple Myeloma
By
Wayne Kuznar
Hematologic Malignancies
,
Multiple Myeloma
,
Personalized Medicine
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Adding the recently approved daratumumab (Darzalex), a human, CD38-directed monoclonal antibody, to a standard regimen of bortezomib (Velcade) and dexamethasone improved progression-free survival (PFS) by >60% compared with the standard regimen in patients with relapsed or refractory multiple myeloma, according to Antonio Palumbo, MD, Chief of the Multiple Myeloma Unit, University of Torino, Italy.
Read Article
Refining the Use of CAR T-Cells in Patients with Acute Lymphoblastic Leukemia
By
Phoebe Starr
Hematologic Malignancies
,
Leukemia
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Chimeric antigen receptor (CAR) T-cells have saved lives in some patients with acute lymphoblastic leukemia (ALL) who had run out of other treatment options. This type of immunotherapy is making inroads in other hematologic malignancies as well, but it is still being studied in very sick patients.
Read Article
CAR T-Cell Therapy Produces High Response Rates in Refractory B-Cell Malignancies
By
Wayne Kuznar
Hematologic Malignancies
,
Leukemia
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
A durable complete response was achieved in a high proportion of adults with refractory B-cell malignancies who received CD19+ chimeric antigen receptor (CAR) T-cells made up of a defined 1:1 ratio of CD8+ and CD4+ cells.
Read Article
Adding Daratumumab to the Treatment Regimen Improves Progression-Free Survival in Patients with Multiple Myeloma
By
Jessica Miller
Hematologic Malignancies
,
Multiple Myeloma
July 2016, Vol 7, No 6
Daratumumab in combination with lenalidomide and dexamethasone achieved a 63% reduction in progression-free survival (PFS) compared with lenalidomide and dexamethasone alone in patients with multiple myeloma who had received at least 1 previous line of therapy, according to study results presented at the 2016 European Hematology Association Annual Congress meeting.
Read Article
Page 8 of 11
2
3
4
5
6
7
8
9
10
11
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
2.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
3.
Epkinly FDA Approved for Treatment of Advanced Diffuse Large B-Cell Lymphoma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma